Chicago Venture Partners

Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.The Company is currently commercializing sugarBEAT® and proBEAT™.sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes.

Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.The Company is currently commercializing sugarBEAT® and proBEAT™.sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes.

GrowLife is a logistics company that serves as a cultivation facility service provider. It provides hydroponic equipment, lighting, nutrients, media, and other cultivation supplies to commercial and urban operations. With a complete selection of cultivation products combined with logistics and distribution services, GrowLife can help responsible cultivation operations efficiently control supply costs, manage build-out investments, track supply usage, and streamline workflows. GrowLife was founded in 1987 and headquartered in Seattle, Washington.

OncoVista Innovative Therapies, Inc., a biopharmaceutical company, focuses on commercializing diagnostic tests for metastatic tumors, as well as developing targeted anticancer therapies by utilizing tumor-associated biomarkers. The company has developed diagnostic kits for breast, colon, ovarian, and prostate cancers, and markets diagnostic kits in Europe for the detection of circulating tumor cells (CTCs) in patients with breast and colon cancer. Product and Product Candidate Pipeline The company's portfolio of compounds and technologies under development or planned development include: AdnaGen Oncology Diagnostics; A Liposomal TS Inhibitor; Cordycepin; L-Nucleoside Conjugates; and Novel Tubulin Isotype-Specific Anti-Mitotics. AdnaGen Diagnostic Products The company's subsidiary, AdnaGen A.G., offers diagnostic products for colon and breast cancer diagnosis in the European market. It has the ability to detect and recognize the expression of tumor-associated biomarkers in patients with metastatic cancer. In September 2008, AdnaGen entered into a distribution and license agreement with Biomarkers LLC (Biomarkers) granting Biomarkers the right to distribute the AdnaGen diagnostic kits in North America. AdnaGen also entered into a distribution and license agreement with Biomarkers granting Biomarkers the right to distribute the AdnaGen diagnostic kits in South America and the Middle East. In January 2007, AdnaGen entered into a distribution agreement with Innogenetics N.V. (Innogenetics) granting Innogenetics the right to commercialize the AdnaGen diagnostic kits in the European market. In September 2007, AdnaGen entered into a license agreement with Innogenetics granting Innogenetics the right to use AdnaGen technology in adapting Innogenetics' proprietary strip detection technology after successful feasibility studies. Liposomal Thymidylate Synthase (TS) Inhibitor (OVI-237) (solid tumors) OVI-237 is the company's advanced clinical stage drug. OVI-237 is a liposome encapsulated formulation of a potent thymidylate synthase inhibitor (TSI) with activity at picomolar concentrations. It was obtained as a result of a worldwide licensing agreement with OSI Pharmaceuticals (Melville, New York). With OVI-237, it has finalized the protocol and selected clinical sites to conduct a Phase II Study of OVI-237 monotherapy and combination therapy with cisplatin for the treatment of metastatic breast cancer. Cordycepin (OVI-123) (TdT-Positive Refractory Leukemias) The company is developing Cordycepin as a treatment option for certain leukemia patients that are either refractory to chemotherapeutics or have experienced a relapse. Cordycepin depends upon the presence of a DNA polymerase, known as terminal deoxynucleotidyl transferase (TdT), for its therapeutic activity. Cordycepin has been studied in a National Cancer Institute-sponsored Phase I clinical trial for treating TdT-positive ALL leukemia patients. It initiated a Phase I/II trial based on the ‘original' ADA-sensitive compound. L-Nucleoside Conjugate (OVI-117): The company has accumulated in vitro and in vivo data indicating that the L-nucleoside conjugates are effective against various types of cancer. One of its L-nucleoside conjugate candidates, OVI-117, is a conjugate of an L-nucleoside (L-uridine) and the highly toxic compound 5'-fluorodeoxyuridine monophosphate (FdUMP), a thymidylate synthase (TS) inhibitor. Tubulin Isotype-Specific Anti-mitotics The company's other platform technology relates to a proprietary database of tubulin isotypes as potential candidates for targeting by certain chemotherapeutics. It is evaluating various candidates as part of its research and development in this area. Collaborative Relationships and Partnerships The company has relationships with the University of Texas Health Science Center at San Antonio (UTHSCSA), the Cancer Therapy and Research Center (CTRC), the Dana-Farber Cancer Institute, MD Anderson Cancer Center and the San Antonio Cancer Institute (SACI), a cancer research institute. Competition The company's competitors include Amgen, Inc.; Genentech, Inc.; Biogen Idec Inc.; Eli Lilly & Co.; OSI Pharmaceuticals, Inc.; Avalon; Kosan; Allos; EntreMed; Threshold Pharmaceuticals; Vion Pharmaceuticals; Cougar Biotechnology; Sunesis; Abbott Diagnostic Laboratories; Aureon Laboratories; Celera Diagnostics, LLC; Correlogic Systems; Genomic Health; Monogram Biosciences; Myriad Genetics; Roche Diagnostics; and Veridex LLC. History OncoVista Innovative Therapies, Inc. was incorporated in 2004.

IKANO Communications was founded over 10 years ago as a regional Internet service provider in the Intermountain West and since then has flourished to become the industry leader in private-label, wholesale, and retail Internet services. IKANO leverages its ISP platform to provide outstanding services at highly competitive prices. The company's rapid growth and excellence in the field have resulted in IKANO's ranking in the Inc. 500, Technology Fast 500, Inner City 100, Utah 100, and Call Center of the Year. The word "ikano" means "to enable" in the Greek language. Thus, IKANO is a leading enabler of Internet services and IP solutions. IKANO provides wholesale telco services for ISP's, turn key services for affinity groups, and retail services for IKANO owned brands. We leverage our relationships with telecommunications companies and CLEC's to help organizations that want to become more effective in acquiring new customers, communicating with customers and retaining customers through their e-business initiatives. As the official Data Networking Services Provider for the 2002 Olympic and Paralympic Winter Games, IKANO provided the data networking services and support for the 2002 Games.